Thoratec Appoints Taylor C. Harris As Chief Financial Officer
PLEASANTON, Calif., Oct. 11, 2012
PLEASANTON, Calif., Oct. 11, 2012 /PRNewswire/ --Thoratec Corporation
(NASDAQ: THOR), a world leader in device-based mechanical circulatory support
(MCS) therapies to save, support and restore failing hearts, today announced
that its Board of Directors has appointed Taylor C. Harris to the position of
Vice President and Chief Financial Officer.
Mr. Harris joined Thoratec in 2010 as Senior Director of Investor Relations
and Business Development. Prior to joining Thoratec, Mr. Harris worked at
JPMorgan Chase & Co. for over a decade in several capacities, including as a
Vice President in the firm's Healthcare Investment Banking and Equity Research
departments. In these roles, Mr. Harris covered the medical device sector as
an investment research analyst and advised healthcare companies on a broad
range of strategic and capital markets transactions. Mr. Harris holds a B.A.
in Physics and Economics from the University of North Carolina at Chapel Hill.
"Over the past few years, Taylor has effectively driven a broad range of
initiatives at Thoratec, demonstrating strong leadership, business knowledge
and strategic vision," commented Gary Burbach, President and Chief Executive
Officer. "We are confident that Taylor will make increasingly valuable
contributions to Thoratec in the CFO role, as we continue to grow our markets
and expand our global business."
Mr. Burbach also expressed the Company's gratitude to Roxanne Oulman, the
company's Vice President of Finance, who has been serving as interim Chief
Financial Officer since June 2011. "We appreciate Roxanne shepherding the
Company's financial functions through this transition period," noted Burbach.
"Thanks to her leadership, we have been able to maintain absolute confidence
in our financial and accounting operations while we engaged in a robust
process to recruit a CFO."
Thoratec is the world leader in mechanical circulatory support with the
broadest product portfolio to treat the full range of clinical needs for
patients suffering from advanced heart failure. The company's products include
the HeartMate LVAS and Thoratec VAD, with more than 20,000 devices implanted
in patients suffering from heart failure. Thoratec also manufactures and
distributes the CentriMag and PediMag / PediVAS product lines. Thoratec is
headquartered in Pleasanton, California. For more information, visit
Thoratec, the Thoratec logo, HeartMate and HeartMate II are registered
trademarks of Thoratec Corporation and IVAD, Thoratec 360, Shared Care and
Thoratec Connect are trademarks of Thoratec Corporation. CentriMag and
PediMag are registered trademarks of Thoratec LLC, and PediVAS is a registered
trademark of Thoratec Switzerland GmbH.
Many of the preceding paragraphs, particularly but not exclusively those
addressing guidance for fiscal 2012 financial results or future performance
contain forward-looking statements within the meaning of Sections 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.
These statements can be identified by the words, "believes," "views,"
"expects," "plans," "projects," "hopes," "could," "will," and other similar
words. Actual results, events or performance could differ materially from
these forward-looking statements based on a variety of factors, many of which
are beyond Thoratec's control. Therefore, readers are cautioned not to put
undue reliance on these statements. Investors are cautioned that all such
statements involve risks and uncertainties, including risks related to the
development of new products and new markets including Destination Therapy, the
growth of existing markets for our products, customer and physician acceptance
of Thoratec products, the ability to improve financial performance, the
effects of healthcare reimbursement and coverage policies, the effects of
competition and the effects of any merger, acquisition and divestiture related
activities. Forward-looking statements contained in this press release should
be considered in light these factors and those factors discussed from time to
time in Thoratec's public reports filed with the Securities and Exchange
Commission, such as those discussed under the heading, "Risk Factors," in
Thoratec's most recent annual report on Form 10-K, quarterly reports on Form
10-Q, current reports on Form 8-K and other SEC filings. These forward-looking
statements speak only as of the date hereof. Thoratec undertakes no obligation
to publicly release the results of any revisions to these forward-looking
statements that may be made to reflect events or circumstances after the date
hereof, or to reflect the occurrence of unanticipated events.
SOURCE Thoratec Corporation
Contact: Taylor Harris, Vice President and Chief Financial Officer,
Press spacebar to pause and continue. Press esc to stop.